UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO) exercised 9,500 options and sold about 9,900 United Therapeutics (UTHR) common shares held by a family trust in multiple trades around $482–$504 per share under a 10b5-1 plan.

On 2026-09-08, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $117.76 per share into 9,500 shares of common stock and then executed a series of open-market sales of those resulting shares and additional trust-held shares. The sales were broken into multiple trades totaling 9,900 shares at prices ranging from approximately $481.91 to $504.15 per share, generating an estimated $4.9–5.0 million in gross proceeds and representing a sizable monetization relative to the option cost basis. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, and the reporting person continues to beneficially own approximately 480,410 shares of United Therapeutics common stock through various direct and indirect holdings, indicating a substantial remaining equity stake despite the significant programmed sales.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000137

Alert Tier

7